神威药业(02877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02877 神威药业

休市中 10-16 16:08:16

7.440

-0.030

-0.40%

最高7.540	最低7.420	成交量61.80万
今开7.435	昨收7.470	日振幅1.61%
总市值61.53亿	流通市值61.53亿	总股本8.27亿
成交额460.65万	换手率0.07%	流通股本8.27亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02877","market":"HK","secType":"STK","nameCN":"神威药业","latestPrice":7.44,"timestamp":1792138096008,"preClose":7.47,"halted":0,"volume":618000,"delay":0,"changeRate":-0.004016064257028027,"floatShares":827000000,"shares":827000000,"eps":1.26,"marketStatus":"休市中","change":-0.03,"latestTime":"10-16 16:08:16","open":7.435,"high":7.54,"low":7.42,"amount":4606504,"amplitude":0.016064,"askPrice":7.44,"askSize":6000,"bidPrice":7.43,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":1.12,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":7,"adr":0,"listingDate":1101916800000,"exchange":"SEHK","adjPreClose":7.47,"dividendRate":0.324556,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":0.6431336635456383,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02877/wiki","defaultTab":"wiki","newsList":[{"id":"2675455167","title":"【券商聚焦】中信证券：市场风格趋于谨慎 中药高股息标的关注度持续上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2675455167","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675455167?lang=zh_cn&edition=full","pubTime":"2026-10-16 08:52","pubTimestamp":1792111979,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券表示，近期，市场风格趋于谨慎，中药高股息标的关注度持续上升。在此背景下，中药板块凭借\"低估值+高股息+成本端改善\"三重属性，成为具备高确定性的细分投资板块。该机构梳理两条投资主线：1）高股息率、业绩稳健标的。2）业绩边际向好、股息率具备一定吸引力的标的。风险因素：渠道库存积压的风险；业绩不及预期的风险；成本上涨的风险；集采不及预期的风险；重大支出后降低股息率的风险。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993818","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","KCE","BK0183","00570","ABEQ","159207","PRIZ","EASY","02273","BK0012","LU2580892862.HKD","FTDS","LU2289578879.USD","CGVV","00874","02877","LU0405327494.USD","BK1197","LU0405327148.USD","600030","BK1516","BK0188","BK1147","BK1570","03320","LU1820825898.SGD","LU2580892789.USD","PY","BK0276","LU1720050803.USD","LU1997244956.HKD","LU1328615791.USD","BK1219","LU1064130708.USD","LU1146622755.USD","03613","BK1191","BK1564","BK1521","LU1064131003.USD","LU1781817850.SGD","LU2148510915.USD","LU1794554557.SGD","01643","06030","02161","LU1580142542.USD","QUSA","LU1255011170.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673044541","title":"中医药板块普涨 绿叶制药（02186）涨2.23%  机构指板块有望迎估值与业绩双重修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2673044541","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673044541?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:45","pubTimestamp":1791423956,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股中医药板块盘初普涨，截至发稿，中国中药 涨4.98%，吉林长龙药业涨3.23%，绿叶制药涨2.23%，白云山涨1.84%，神威药业涨1.42%，华润医药涨1.05%。随着基药目录红利的Q4落地、库存周期的边际改善以及成本红利的持续释放，板块有望迎来估值与业绩的双重修复。OTC板块核心变量是成本下行和渠道去库，Q4呼吸系统疾病发病率若季节性回升，感冒呼吸类OTC终端动销有望回暖；消费中药若消费环境边际回暖，品牌中药的收入端弹性较大。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993277","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320","BK1197","BK1191","00570","08049","BK1521","BK1515","BK1583","02877","00874","BK1570","02186","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162348547","title":"神威药业9月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1162348547","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162348547?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:25","pubTimestamp":1790760357,"startTime":"0","endTime":"0","summary":"中国神威药业集团有限公司于2026年9月30日发布2026年9月股份变动月报表。公告显示，截至2026年9月30日，公司法定（注册）股本仍为5,000,000,000股，面值为每股0.1港元，法定股本总额为5亿港元，较上月无变动。公司披露，相关股份数量符合香港联合交易所有限公司上市规则的最低公众持股量要求。公司确认遵守香港联交所《上市规则》及其他相关法律规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199501192","title":"神威药业（02877）公布自2026年10月1日起董事会及各专门委员会组成","url":"https://stock-news.laohu8.com/highlight/detail?id=1199501192","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199501192?lang=zh_cn&edition=full","pubTime":"2026-09-29 12:05","pubTimestamp":1790654741,"startTime":"0","endTime":"0","summary":"2026年9月29日，中国神威药业集团有限公司发布公告，披露自2026年10月1日起的董事会成员及其在董事会下设四个专门委员会中的职务安排。本次调整自2026年10月1日起生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118783920","title":"神威药业（02877.HK）：执行董事信蘊霞将于2026年10月1日退休并同步调整董事会委员会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1118783920","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118783920?lang=zh_cn&edition=full","pubTime":"2026-09-29 12:05","pubTimestamp":1790654730,"startTime":"0","endTime":"0","summary":"神威药业（02877.HK）9月29日公告，公司执行董事信蘊霞女士已届退休年龄，其与公司签订的董事合约将于2026年9月30日届满，届时她将于2026年10月1日正式退任执行董事。信蘊霞女士确认其与董事会没有意见分歧，亦无其他需要提请股东注意的事宜。董事会对其在任期内的贡献表示感谢。\n信蘊霞女士退休后，将同时不再担任公司薪酬委员会及企业社会责任与可持续发展委员会成员。公司已委任李惠民先生自2026年10月1日起接任上述两个委员会的成员。\n截至公告日，公司董事会组成如下：执行董事为李振江先生、信蘊霞女士及李惠民先生；非执行董事为周文成先生；独立非执行董事为廖舜辉先生、姚逸安先生及王桂华女士。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671260926","title":"神威药业(02877.HK)：信蕴霞将退任执行董事职务","url":"https://stock-news.laohu8.com/highlight/detail?id=2671260926","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671260926?lang=zh_cn&edition=full","pubTime":"2026-09-29 12:05","pubTimestamp":1790654721,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02877","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175417123","title":"神威药业2026年中期营收11.81亿元，经调整净利润4.69亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175417123","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175417123?lang=zh_cn&edition=full","pubTime":"2026-09-28 10:43","pubTimestamp":1790563384,"startTime":"0","endTime":"0","summary":"神威药业披露截至2026年6月30日止六个月财务数据，报告期内实现营业额11.81亿元，同比下降28.5%；经调整净利润为4.69亿元，同比下降23.7%。毛利率为72.2%，同期为69.9%。报告期内经营活动产生的现金净流入约2.73亿元。注射液实现收入3.20亿元，同比下降43.4%；软胶囊收入2.03亿元，同比下滑6.8%；颗粒剂收入2.47亿元，同比减少9.6%；中药配方颗粒收入3.36亿元，同比降低31.1%；其他剂型收入0.76亿元，同比下降30.6%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"神威药业2026年中期营收11.81亿元，经调整净利润4.69亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668912975","title":"神威药业(02877)将于10月15日派发特别中期股息每股0.85元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668912975","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668912975?lang=zh_cn&edition=full","pubTime":"2026-09-18 12:21","pubTimestamp":1789705287,"startTime":"0","endTime":"0","summary":"智通财经APP讯，神威药业(02877)发布公告，该公司将于2026年10月15日派发2026年财政年度特别中期股息每股人民币0.85元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VIG","BK1191","BK1606","BK4588","02877","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668912377","title":"神威药业：10月15日将派发股息0.995港元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668912377","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668912377?lang=zh_cn&edition=full","pubTime":"2026-09-18 12:08","pubTimestamp":1789704484,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1606","BK1191","02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666307868","title":"港股异动 | 神威药业(02877)午后涨超9% 公司携多款中成药参与2026年医保国谈竞价","url":"https://stock-news.laohu8.com/highlight/detail?id=2666307868","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666307868?lang=zh_cn&edition=full","pubTime":"2026-09-09 13:54","pubTimestamp":1788933295,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，神威药业午后涨超9%。消息面上，9月8日，基本医保谈判上午收官，神威药业携芍药甘草汤颗粒、桃红四物汤颗粒等多款中成药参与竞价。值得注意的是，2026年版《国家基本药物目录》于9月1日正式落地，神威药业有4款中药注射剂及多款独家中成药此前成功入选。神威药业中期财报显示，上半年营业额11.81亿元人民币，同比减少28.5%；期内溢利4.69亿元，同比减少23.7%；拟派发第二次中期股息80分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493775.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02877","VXUS","BK4588","KCAI","BK1191","BK1606","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665646344","title":"神威药业(02877.HK)9月18日举行董事会会议考虑向股东宣派特别中期股息","url":"https://stock-news.laohu8.com/highlight/detail?id=2665646344","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665646344?lang=zh_cn&edition=full","pubTime":"2026-09-08 12:27","pubTimestamp":1788841621,"startTime":"0","endTime":"0","summary":"格隆汇9月7日丨神威药业(02877.HK)宣布，董事会将于2026年9月18日星期五举行董事会会议，藉以考虑向公司股东宣派特别中期股息。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260908/32363114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02877","BK1606","BK1191","BK4588","BK4585","VIG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190897940","title":"神威药业：董事会拟于9月18日召开会议审议特别中期股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1190897940","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190897940?lang=zh_cn&edition=full","pubTime":"2026-09-08 12:06","pubTimestamp":1788840386,"startTime":"0","endTime":"0","summary":"中国神威药业集团有限公司（02877）9月8日发布董事会会议通知称，董事会计划于2026年9月18日（星期五）召开会议，届时将审议并考虑向股东宣派特别中期股息等事项。公司表示，将在会议后及时披露相关决议结果。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115054932","title":"神威药业8月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1115054932","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115054932?lang=zh_cn&edition=full","pubTime":"2026-09-01 16:33","pubTimestamp":1788251597,"startTime":"0","endTime":"0","summary":"中国神威药业集团有限公司（股票代码：02877）于2026年9月1日披露截至2026年8月31日的股份变动月报。根据公告，报告期内公司法定注册股本维持在5,000,000,000股，面值每股0.1港元，总额500,000,000港元，未出现增减变动。\n同期，公司已发行股份数量为827,000,000股，并无库存股，较上月无增减变化。公告显示，报告期内公司未进行任何股份发行、股份购回或注销，也未有股权激励及期权变动事项。公司确认当前已满足适用的公众持股量要求，股本总体保持稳定。\n公告由公司秘书李品正签署，公司声明将继续遵守香港联合交易所有限公司相关上市规则及适用法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775280","title":"神威药业午后涨逾5% 上半年营业额11.81亿元同比减少28.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775280","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662775280?lang=zh_cn&edition=full","pubTime":"2026-08-27 14:54","pubTimestamp":1787813640,"startTime":"0","endTime":"0","summary":"模拟交易客户端神威药业午后一度飙升12%，截至发稿，股价上涨4.92%，现报8.33港元，成交额5423.40万港元。神威药业发布中期业绩，上半年营业额11.81亿元人民币，同比减少28.5%；期内溢利4.69亿元，同比减少23.7%；每股基本盈利62分；拟派发第二次中期股息80分。于2026年首6个月，口服产品占总销售额的比例达72.9% ，而注射液产品则占总销售额27.1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-27/doc-inipttax5893795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02877","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778977","title":"港股异动 | 神威药业(02877.HK)午后飙升12% 上半年业绩下滑超两成 拟派发第二次中期股息80分","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778977","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662778977?lang=zh_cn&edition=full","pubTime":"2026-08-27 13:41","pubTimestamp":1787809288,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1606","BK1191","02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662727991","title":"神威药业(02877)发布中期业绩 期内溢利4.69亿元 同比减少23.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662727991","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662727991?lang=zh_cn&edition=full","pubTime":"2026-08-27 12:12","pubTimestamp":1787803973,"startTime":"0","endTime":"0","summary":"智通财经APP讯，神威药业 发布2026年中期业绩，该集团期内取得营业额11.81亿元人民币，同比减少28.5%;期内溢利4.69亿元，同比减少23.7%;每股基本盈利62分;拟派发第二次中期股息80分。清开灵注射液和参麦注射液销售额比去年同期分别减少49.0%及51.3% ，而舒血宁注射液、冠心宁注射液、及丹参注射液等多个注射液产品的销售额亦分别减少39.1%、23.7%及 34.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02877","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190311861","title":"神威药业二零二六年中期营收11.81亿元 净利润4.69亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190311861","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190311861?lang=zh_cn&edition=full","pubTime":"2026-08-27 12:06","pubTimestamp":1787803577,"startTime":"0","endTime":"0","summary":"神威药业公布二零二六年中期财报，实现营业收入11.81亿元，同比下降28.5%。期内净利润4.69亿元，同比下降23.7%。毛利率为69.9%，较上年同期的72.2%有所下滑。成本方面，销售及分销成本下降51.8%，占营业额比重由上年同期的39.2%降至26.4%；行政开支同比减少15.5%，占营业额比重由上年同期的7.7%升至9.0%；研发投入占比5.7%，上年同期为3.0%。神威药业以注射液与口服制剂为主要业务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"神威药业二零二六年中期营收11.81亿元 净利润4.69亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109912163","title":"神威药业定于2026年8月27日召开董事会审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1109912163","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109912163?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:36","pubTimestamp":1786955803,"startTime":"0","endTime":"0","summary":"中国神威药业集团有限公司（02877）8月17日公告，公司董事会将于2026年8月27日（星期四）召开会议，拟审议并批准截至2026年6月30日止六个月的中期业绩，同时考虑宣派股息事宜。\n公告显示，公司现任董事会成员包括：  \n1. 执行董事：李振江、信蕴霞、李惠民  \n2. 非执行董事：周文成  \n3. 独立非执行董事：廖舜辉、姚逸安、王桂华\n以上会议结果及相关财务数据将在会后发布。公司提醒投资者留意后续公告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171658554","title":"神威药业7月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1171658554","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171658554?lang=zh_cn&edition=full","pubTime":"2026-08-03 15:40","pubTimestamp":1785742843,"startTime":"0","endTime":"0","summary":"2026年8月3日，中国神威药业集团有限公司公布截至2026年7月31日的每月证券变动情况。根据月报显示，公司报告期内注册股本及已发行股本均维持稳定，未发生新增发行、回购或注销股份等变化。另据公告，由于本月未进行股权激励、期权计划或其他涉及发行人股份的协议安排，上述股份总数保持不变。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651584492","title":"【券商聚焦】光大证券：议优先布局经营稳健、业绩扎实或者股息类中药标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2651584492","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651584492?lang=zh_cn&edition=full","pubTime":"2026-07-16 08:54","pubTimestamp":1784163265,"startTime":"0","endTime":"0","summary":"金吾财讯 | 光大证券研究指，近期，中药板块持续上涨，主要受到市场避险、政策利好、业绩催化和估值底部等多重因素共同推动，中期配置价值显著，后市偏乐观。建议优先布局经营稳健、业绩扎实或者高股息类中药标的。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985990","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1564","BK4588","02877","BK0012","02161","BK1521","VIG","BK0276","BK0183","BK1147","02273","BK1191","03613","00874","KCE","BK1515","BK1606","601788","06178","BK0028","BK0188","BK1197","00570","BK4585","01643","BK1570","03320","BK1219"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shineway.com.hk","stockEarnings":[{"period":"1week","weight":0.002},{"period":"1month","weight":0.0507},{"period":"3month","weight":0.1494},{"period":"6month","weight":0.0129},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.1636}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国神威药业集团有限公司是一家主要从事中药产品研发、制造及买卖的投资控股公司。该公司的产品剂型包括注射液、软胶囊、颗粒剂、中药（TCM）配方颗粒、口服产品及其他剂型。该公司的产品包括清开灵注射液、参麦注射液、五福心脑清软胶囊、清开灵软胶囊、滑膜炎颗粒、复方甘草片等产品，应用于流感、心脑血管、呼吸系统等疾病领域。该公司在中国大陆和香港市场运营其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.681818,"avgChangeRate":0.030915},{"month":2,"riseRate":0.545455,"avgChangeRate":0.033555},{"month":3,"riseRate":0.590909,"avgChangeRate":0.015705},{"month":4,"riseRate":0.681818,"avgChangeRate":0.04997},{"month":5,"riseRate":0.5,"avgChangeRate":0.030756},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.02559},{"month":7,"riseRate":0.227273,"avgChangeRate":-0.052696},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.000561},{"month":9,"riseRate":0.363636,"avgChangeRate":0.005216},{"month":10,"riseRate":0.681818,"avgChangeRate":0.016526},{"month":11,"riseRate":0.52381,"avgChangeRate":0.056896},{"month":12,"riseRate":0.47619,"avgChangeRate":-0.002685}],"exchange":"SEHK","name":"神威药业","nameEN":"SHINEWAY PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神威药业(02877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神威药业(02877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神威药业,02877,神威药业股票,神威药业股票老虎,神威药业股票老虎国际,神威药业行情,神威药业股票行情,神威药业股价,神威药业股市,神威药业股票价格,神威药业股票交易,神威药业股票购买,神威药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神威药业(02877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神威药业(02877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}